Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
Subscribe To Our Newsletter & Stay Updated
